NasdaqGM - Delayed Quote USD

Vaxxinity, Inc. (VAXX)

0.1166 -0.0048 (-3.95%)
At close: April 26 at 4:00 PM EDT
0.1150 -0.00 (-1.37%)
After hours: April 26 at 7:45 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
--
--
--
66.0000
557.0000
Cost of Revenue
--
--
--
1,937.0000
52.0000
Gross Profit
--
--
--
-1,871.0000
505.0000
Operating Expense
58,285.0000
58,285.0000
75,979.0000
123,204.0000
32,787.0000
Operating Income
-58,285.0000
-58,285.0000
-75,979.0000
-125,075.0000
-32,282.0000
Net Non Operating Interest Income Expense
1,394.0000
1,394.0000
745.0000
-831.0000
-1,181.0000
Other Income Expense
-43.0000
-43.0000
12.0000
-11,269.0000
-6,494.0000
Pretax Income
-56,934.0000
-56,934.0000
-75,222.0000
-137,175.0000
-39,957.0000
Net Income Common Stockholders
-56,934.0000
-56,934.0000
-75,222.0000
-137,175.0000
-39,957.0000
Diluted NI Available to Com Stockholders
-56,934.0000
-56,934.0000
-75,222.0000
-137,175.0000
-39,957.0000
Basic EPS
-0.45
--
-0.60
-1.79
-0.32
Diluted EPS
-0.45
--
-0.60
-1.79
-0.32
Basic Average Shares
126,508.9170
--
125,939.0500
76,586.8420
124,753.1780
Diluted Average Shares
126,508.9170
--
125,939.0500
76,586.8420
124,753.1780
Total Operating Income as Reported
-58,285.0000
-58,285.0000
-75,979.0000
-125,075.0000
-32,282.0000
Total Expenses
58,285.0000
58,285.0000
75,979.0000
125,141.0000
32,839.0000
Net Income from Continuing & Discontinued Operation
-56,934.0000
-56,934.0000
-75,222.0000
-137,175.0000
-39,957.0000
Normalized Income
-56,891.0000
-56,891.0000
-75,234.0000
-125,906.0000
-33,463.0000
Interest Income
2,090.0000
2,090.0000
1,259.0000
9.0000
1.0000
Interest Expense
696.0000
696.0000
514.0000
840.0000
1,182.0000
Net Interest Income
1,394.0000
1,394.0000
745.0000
-831.0000
-1,181.0000
EBIT
-56,238.0000
-56,238.0000
-74,708.0000
-136,335.0000
-38,775.0000
EBITDA
-54,004.0000
-54,004.0000
-73,024.0000
-135,233.0000
-38,058.0000
Reconciled Cost of Revenue
--
--
--
1,937.0000
52.0000
Reconciled Depreciation
2,234.0000
2,234.0000
1,684.0000
1,102.0000
717.0000
Net Income from Continuing Operation Net Minority Interest
-56,934.0000
-56,934.0000
-75,222.0000
-137,175.0000
-39,957.0000
Total Unusual Items Excluding Goodwill
-43.0000
-43.0000
12.0000
-11,269.0000
-6,494.0000
Total Unusual Items
-43.0000
-43.0000
12.0000
-11,269.0000
-6,494.0000
Normalized EBITDA
-53,961.0000
-53,961.0000
-73,036.0000
-123,964.0000
-31,564.0000
12/31/2020 - 11/11/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

KTRA Kintara Therapeutics, Inc.
0.1488
-5.82%
 
PHIO Phio Pharmaceuticals Corp.
0.6820
+1.34%
 
FNCH Finch Therapeutics Group, Inc.
2.3200
+3.11%
 
ASLN ASLAN Pharmaceuticals Limited
0.4153
-7.30%
 
HEPA Hepion Pharmaceuticals, Inc.
1.3700
+6.20%
 
TOVX Theriva Biologics, Inc.
0.4195
+2.33%
 
NKGN NKGen Biotech, Inc.
1.6100
-18.69%
 
TVGN Tevogen Bio Holdings Inc.
1.0000
+17.65%
 
ABEO Abeona Therapeutics Inc.
3.2600
+2.19%
 
PRTG Portage Biotech Inc.
0.2402
-4.95%